March 30, 2020 — Smokers who received smoking cessation counseling and used electronic cigarettes (e-cigarettes) containing nicotine were more than twice as likely to successfully quit smoking compared to those who received counseling but did not use e-cigarettes, in a clinical trial presented at the American College of Cardiology (ACC) 2020 Scientific Session.

Researchers cautioned, however, that the health effects of e-cigarettes are unknown, and they should not be used for any purpose other than smoking cessation.

March 30, 2020 — Patients undergoing coronary bypass graft (CAGB) surgery lived longer and had better outcomes when surgeons used a segment of the radial artery from their arm, instead a saphenous vein from their leg, according to research presented at the American College of Cardiology (ACC) 2020 Scientific Session.

March 30, 2020 — Edwards Lifesciences Corp. announced it is temporarily pausing new enrollments in its active pivotal clinical trials of transcatheter mitral and tricuspid therapies. This is in response to the urgent novel coronavirus (COVID-19) response around the globe.

March 30, 2020 — A group of 13 U.S. medical societies sent an open letter to Congress appealing to them to do what is needed to ensure the supply of critically needed medical equipment in the fight against novel coronavirus (COVID-19, SARS-CoV-2).

March 30, 2020 — Patients in the United Kingdom (U.K.) who underwent transcatheter aortic valve replacement (TAVR) did not have a higher rate of death at one year compared with those who had their heart valve replaced via open-heart surgery, according to research presented at the American College of Cardiology (ACC) 2020 Annual Scientific Session.


March 30, 2020 — Low-risk patients undergoing transcatheter aortic valve repair (TAVR) at two years did just as well compared with those undergoing open heart valve replacement surgery in the PARTNER 3 low-risk trial. The two-year results presented at the American College of Cardiology (ACC) 2020 Annual Scientific Session


March 29, 2020 — Worse than expected outcomes were found for survival and quality of life among patients undergoing transcatheter aortic valve replacement (TAVR) at 34 medical centers in the United States. This was according to a study of 11 percent of U.S.

March 29, 2020 — Patients with worsening heart failure and reduced ejection fraction who received the investigational drug vericiguat had a significantly lower rate of cardiovascular death or heart failure hospitalization compared with those receiving a placebo, based on research presented at the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).


March 29, 2020 — Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replacement (TAVR) procedures had a high rate of success and low risk of death or disabling stroke at 30 days, according to new data presented at the American College of Cardiology (ACC) 2020 Scientific Session. The session was part of the virtual, online late-breaking presentations, since the live meeting was cancelled due to the spread of COVID-19. 


March 29, 2020 — Patients with atrial fibrillation (AF) who took oral anticoagulants alone after undergoing transcatheter aortic valve replacement (TAVR) had a lower rate of bleeding complications without an increased risk of clotting-related complications compared to patients who took antiplatelet medication in addition to oral anticoagulants. This was the outcome of the POPULAR TAVR trial, presented as a late-breaking session at the American College of Cardiology (ACC) 2020 Scientific Session.[1]

Subscribe Now